Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact

Citations to this article

Identification of epitopes in ovalbumin that provide insights for cancer neoepitopes
Sukrut Hemant Karandikar, … , Alan Jerry Korman, Pramod Kumar Srivastava
Sukrut Hemant Karandikar, … , Alan Jerry Korman, Pramod Kumar Srivastava
Published March 14, 2019
Citation Information: JCI Insight. 2019;4(8):e127882. https://doi.org/10.1172/jci.insight.127882.
View: Text | PDF
Research Article Immunology Article has an altmetric score of 3

Identification of epitopes in ovalbumin that provide insights for cancer neoepitopes

  • Text
  • PDF
Abstract

MHC I–restricted epitopes of chicken ovalbumin (OVA) were originally identified using CD8+ T cells as probes. Here, using bioinformatics tools, we identify 4 additional epitopes in OVA in addition to a cryptic epitope. Each additional epitope is presented in vivo, as deduced from the lack of CD8+ T cell response to it in OVA-transgenic mice. In addition, CD8 responses to the previously known epitopes and those identified in this study are examined in C57BL/6J mice exposed to the OVA-expressing tumor E.G7 in several ways. No responses to any epitope, including SIINFEKL, are detected in mice with growing E.G7 or mice immunized with the tumor. Only in E.G7-bearing mice treated with an anti–CTLA-4 antibody, which depletes tumor-infiltrating regulatory T cells, are CD8 responses to SIINFEKL and the epitope EKYNLTSVL identified in this study detected. Finally, all epitopes fail to treat mice with preexisting tumors. These observations force an important reconsideration of the common assumptions about the therapeutic value of neoepitopes detected by CD8 responses in tumor-bearing hosts.

Authors

Sukrut Hemant Karandikar, John Sidney, Alessandro Sette, Mark Joseph Selby, Alan Jerry Korman, Pramod Kumar Srivastava

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2019 Total
Citations: 2 3 1 2 6 1 15
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (15)

Title and authors Publication Year
Antigenic peptide delivery to antigen-presenting cells using a CD40-coiled coil affinity-based platform
Nyesiga B, Hägerbrand K, Varas L, Gjörloff Wingren A, Ohlin M, Ellmark P, von Schantz L
Drug Delivery 2025
A frameshift-generated cancer neoepitope that controls tumor burden in prophylaxis as well as therapy
George MM, Brennick CA, Hagymasi AT, Shcheglova TV, Al Seesi S, Rosales TJ, Baker BM, Mandoiu II, Srivastava PK
The Journal of Immunology Author Choice 2025
Cancer neoepitopes: Awaiting “the simplicity on the other side of complexity”
Pramod K. Srivastava
Journal of Clinical Investigation 2024
Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy.
Gujar S, Pol JG, Kumar V, Lizarralde-Guerrero M, Konda P, Kroemer G, Bell JC
Nature Protocols 2024
Impact of hydrophobic modification on biocompatibility of Alaska pollock gelatin microparticles.
Yee YC, Mori T, Ito S, Taguchi T, Katayama Y
2024
CD8+ T Cell-Dependent Antitumor Activity In Vivo of a Mass Spectrometry-Identified Neoepitope despite Undetectable CD8+ Immunogenicity In Vitro.
Gillig MA, Brennick CA, George MM, Balsbaugh JL, Shcheglova TV, Mandoiu II, Rosales T, Baker BM, Srivastava PK, Karandikar SH
Journal of immunology (Baltimore, Md. : 1950) 2023
Utility of a Recombinant HSV-1 Vaccine Vector for Personalized Cancer Vaccines
I Uche, B Stanfield, J Rudd, K Kousoulas, P Rider
Frontiers in Molecular Biosciences 2022
Recent advances in surface modification of micro- and nano-scale biomaterials with biological membranes and biomolecules.
Abesekara MS, Chau Y
Frontiers in Bioengineering and Biotechnology 2022
An unbiased approach to defining bona fide cancer neoepitopes that elicit immune-mediated cancer rejection
Cory A. Brennick, Mariam M. George, Marmar R. Moussa, Adam T. Hagymasi, Sahar Al Seesi, Tatiana V. Shcheglova, Ryan P. Englander, Grant L.J. Keller, Jeremy L. Balsbaugh, Brian M. Baker, Andrea Schietinger, Ion I. Mandoiu, Pramod K. Srivastava
Journal of Clinical Investigation 2021
Systemic inhibition of PTPN22 augments anticancer immunity
Won Jin Ho, Sarah Croessmann, Jianping Lin, Zaw H. Phyo, Soren Charmsaz, Ludmila Danilova, Aditya A Mohan, Nicole Gross, Fangluo Chen, Jiajun Dong, Devesh Aggarwal, Yunpeng Bai, Janey Wang, Jing He, James m Leatherman, Mark Yarchoan, Todd D. Armstrong, Neeha Zaidi, Elana J Fertig, Joshua C Denny, Ben Park, Zhong-Yin Zhang, Elizabeth Jaffee
Journal of Clinical Investigation 2021
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer
PM Westcott, NJ Sacks, JM Schenkel, ZA Ely, O Smith, H Hauck, AM Jaeger, D Zhang, CM Backlund, MC Beytagh, JJ Patten, R Elbashir, G Eng, DJ Irvine, OH Yilmaz, T Jacks
2021
Technical choices significantly alter the adaptive immune response against immunocompetent murine gliomas in a model-dependent manner
B Noffsinger, A Witter, N Sheybani, A Xiao, L Manigat, Q Zhong, S Taori, T Harris, T Bullock, R Price, B Purow
Journal of Neuro-Oncology 2021
Nanocarrier-Based Drug Delivery for Melanoma Therapeutics
M Song, C Liu, S Chen, W Zhang
International journal of molecular sciences 2021
A Combined Adjuvant TF–Al Consisting of TFPR1 and Aluminum Hydroxide Augments Strong Humoral and Cellular Immune Responses in Both C57BL/6 and BALB/c Mice
Q Li, Z Liu, Y Liu, C Liang, J Shu, X Jin, C Li, Z Kou
Human vaccines 2021
Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer
AJ McGray, RY Huang, S Battaglia, C Eppolito, A Miliotto, KB Stephenson, AA Lugade, G Webster, BD Lichty, M Seshadri, D Kozbor, K Odunsi
Journal for ImmunoTherapy of Cancer 2019

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts

Posted by 5 X users
76 readers on Mendeley
See more details